Whether disclosure of drug list prices in direct-to-consumer (DTC) TV commercials should be a condition of participation in the US Medicare and Medicaid programs is just one of many issues on which the Trump Administration seeks public comment in its price transparency proposed rule.
The Centers for Medicare and Medicaid Services (CMS), which issued the rule, also is requesting comment on whether wholesale acquisition cost (WAC) is the most appropriate price to be disclosed in DTC ads, the language and graphical requirements for such
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?